Allarity Therapeutics is a Denmark-based biopharmaceutical company. Its patent-protected mRNA-based DRP platform enables the identification of patients with gene expression highly likely to respond to treatment. It is advancing the PARP inhibitor stenoparib (2X-121), the TKI dovitinib and microtubule inhibitor Ixempra.
Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. Oncology Venture’s goal is to then develop its portfolio of drugs that are active within populations that the DRP can identify. The company recently focused its strategy on three lead assets: the TKI dovitinib, the PARP inhibitor stenoparib, and the microtubule inhibitor agent Ixempra.
Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost; it may then out-license them after clinical validation.